Promatix Biosciences Presents Data on Bispecific Discovery Platform at AACR 2026

Promatix Biosciences presented data at AACR 2026 on its Logic-Gated Proteomics-Driven Bispecific Discovery Platform, which aims to expand the tumour-selective target space for next-generation ADCs. The platform combines proteomic profiling with computational modelling to identify antigen pairs, with experimental validation of a novel EGFR × EphA2 bispecific candidate for colorectal cancer.

By Promatix Biosciences, Ltd. · GlobeNewsWire · April 21, 2026, 09:00 UTC

Topics: AACR 2026 ADC development biotechnology cancer therapy proteomics

Read the full article at GlobeNewsWire

More World news

Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC